Suppr超能文献

印度尼西亚宫颈癌患者健康相关生活质量评估

Evaluation of Health-Related Quality of Life among Patients with Cervical Cancer in Indonesia.

作者信息

Endarti Dwi, Riewpaiboon Arthorn, Thavorncharoensap Montarat, Praditsitthikorn Naiyana, Hutubessy Raymond, Kristina Susi Ari

机构信息

Division of Social and Administrative Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand E-mail :

出版信息

Asian Pac J Cancer Prev. 2015;16(8):3345-50. doi: 10.7314/apjcp.2015.16.8.3345.

Abstract

BACKGROUND

Evaluation of health-related quality of life (HRQOL) in cervical cancer patients is important in order to design the interventions for improving patient outcomes. Reports of HRQOL among cervical cancer patients in Indonesia are limited. Moreover, measurement using EQ-5D-3L is to our best knowledge has hitherto not been performed. This study aimed to examine the HRQOL of cervical cancer patients in Indonesia using EQ- 5D-3L.

MATERIALS AND METHODS

A cross-sectional study was conducted by interviewing cervical cancer patients using the EQ-5D-3L questionnaire. Percentages of patients who reported having problems in each dimension of EQ-5D as well as EQ-5D index score (utility) were calculated.

RESULTS

Our findings indicated that the most frequent reported problems were pain/discomfort (67.8%) followed by anxiety/depression (57.5%). The mean of EQ-5D VAS was 75.8 (SD=17.0). The mean (SD) utility scores were 0.85 (0.19), 0.76 (0.20), 0.71 (0.21), and 0.77 (0.13) for cervical cancer patients in stage I, II, III, and IV, respectively.

CONCLUSIONS

Cervical cancer significantly affects patient HRQOL. Efforts should be made to improve the quality of life of cervical cancer patients especially in terms of pain /discomfort and anxiety/depression reduction.

摘要

背景

评估宫颈癌患者的健康相关生活质量(HRQOL)对于设计改善患者预后的干预措施至关重要。印度尼西亚宫颈癌患者的HRQOL报告有限。此外,据我们所知,尚未使用EQ-5D-3L进行测量。本研究旨在使用EQ-5D-3L评估印度尼西亚宫颈癌患者的HRQOL。

材料与方法

采用横断面研究,使用EQ-5D-3L问卷对宫颈癌患者进行访谈。计算在EQ-5D各维度报告有问题的患者百分比以及EQ-5D指数得分(效用值)。

结果

我们的研究结果表明,最常报告的问题是疼痛/不适(67.8%),其次是焦虑/抑郁(57.5%)。EQ-5D视觉模拟量表(VAS)的平均值为75.8(标准差=17.0)。I期、II期、III期和IV期宫颈癌患者的平均(标准差)效用得分分别为0.85(0.19)、0.76(0.20)、0.71(0.21)和0.77(0.13)。

结论

宫颈癌显著影响患者的HRQOL。应努力提高宫颈癌患者的生活质量,特别是在减轻疼痛/不适和焦虑/抑郁方面。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验